What are the semaglutide prescription requirements for diabetes patients at a first visit?

Does having type 2 diabetes change what a prescriber looks at on a first visit?

Yes, and in several directions at once. A prescriber reviewing a first request for semaglutide from someone with type 2 diabetes will want to understand your current treatment regimen, your HbA1c trajectory, and whether you are already on any other GLP-1 medicine. If you take Ozempic or another semaglutide product for diabetes, adding Wegovy would mean doubling up on the same active ingredient, something no responsible prescriber will do. That fact alone shapes the consultation significantly.

Beyond duplication risk, the prescriber will consider your BMI. The Wegovy SmPC sets out licensed eligibility for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition; type 2 diabetes counts as that condition, so many patients with diabetes do meet the weight criterion. What isn't automatic is NHS access. NHS Wegovy eligibility for weight management currently requires referral to a specialist service, and the criteria are more layered than the licensed thresholds alone. You can read more about the broader requirements for a Wegovy prescription in the UK, including what private routes ask for.

One thing the prescriber will also check: whether your diabetes is managed well enough for a weight-loss medicine to be appropriate right now. Poorly controlled blood glucose changes the benefit-risk calculation. That's a clinical judgement, not something a checklist resolves.

What documentation or information should you bring to a first consultation?

A first consultation for semaglutide weight management when you already have type 2 diabetes works best when the prescriber can see the full picture quickly. In practice, that means being ready to share your current medications (including doses), your most recent HbA1c result if you have it, and any relevant history around your kidneys or pancreas, both of which appear in the contraindication and caution sections of the semaglutide prescribing framework.

A history of pancreatitis is one of the conditions that requires careful prescriber discussion before any GLP-1 medicine is started. The MHRA issued a specific safety communication on pancreatitis risk with GLP-1 medicines in January 2026, noting that severe and persistent stomach pain radiating to the back should prompt urgent medical attention; patients with a prior episode need to raise that history explicitly at a first visit. Details of the MHRA's ongoing monitoring are published on the Yellow Card reporting portal.

If you are currently managed with insulin alongside other diabetes medicines, the prescriber needs to know, because GLP-1 medicines can lower blood glucose further and doses of insulin or sulphonylureas may need adjusting. That's a conversation for your diabetes team as well as the prescribing pharmacist. Bringing a current repeat prescription list, or accessing your NHS Summary Care Record summary, makes the review faster and safer.

Is it safe to move from Ozempic to Wegovy, or to take both?

Taking both is not appropriate, they contain the same active ingredient, semaglutide, and prescribing both simultaneously would mean exceeding any licensed dose without clinical justification. The prescription requirement for Wegovy exists precisely so that a qualified clinician can catch this kind of overlap before it becomes a problem.

Moving from Ozempic to Wegovy is a different question. Some patients with type 2 diabetes who are also eligible for weight management may find a prescriber considers switching, particularly if their diabetes is managed through diet and lifestyle alone or with medicines that don't depend on the Ozempic dose for glucose control. That switch is not straightforward, diabetes management must not be compromised, and the decision sits with the prescriber and, where relevant, the patient's GP or diabetes specialist. Wegovy's UK licence covers weight management, not diabetes; any switch carries implications for both conditions simultaneously.

What is known clearly: semaglutide at weight-management doses has been studied in people with type 2 diabetes in the STEP 2 trial, published in The Lancet, which showed meaningful weight reduction alongside glycaemic improvements. What remains uncertain is how those trial findings translate to your individual regimen, which is exactly the uncertainty a prescriber's assessment is designed to resolve.

What happens if you don't yet meet NHS criteria, are there private options?

Many people with type 2 diabetes find they are in a gap: they meet the licensed weight-management thresholds for semaglutide but are not yet eligible under the phased NHS rollout, or their GP practice has not yet joined the new prescribing pathway. Private prescribing through a regulated pharmacy is a legal alternative, provided a full clinical assessment takes place first, and it is worth understanding why services that offer to supply Wegovy online without a consultation are not a safe or compliant route.

At nume, a GPhC-registered Independent Prescriber reviews every first consultation personally, a clinician reads your answers, not a screening algorithm. The GPhC registration of our pharmacy (number 9012878) is verifiable directly at the GPhC pharmacy register. For anyone with type 2 diabetes, that review includes your existing treatment, not just your BMI, because the two cannot sensibly be separated. You can explore Wegovy pricing in the UK private market for context, and if you're ready to talk to a prescriber, start your free consultation here. Pregnancy, breastfeeding, and trying to conceive are situations where semaglutide is not recommended; those situations require a direct conversation with a doctor before any weight-management medicine is considered.